Sign in
CompletedNo phase

Evaluating Mitochondrial Dysfunction in Patients With Neurofibromatosis Type 1

Key facts

Who runs it
University of Arkansas
Where
Little Rock, United StatesSee the site
Trial code
Status
Completed
People taking part
55 people enrolled
Started
26 Jul 2023
Ended
23 Aug 2024
Type of study
Observational, 2 groups
Treatments tested
  • Blood draw
  • FACIT-F and Pain Scales
Record updated
8 May 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 3 criteriaShow less

Who can take part

  • Diagnosed with NF1
  • Not the first degree relative (biological parent, sibling, or child) of the NF1 patient who is in the NF1 group

Other criteria

  • NF1 Group:

Where in United States

  • University of Arkansas for Medical SciencesLittle Rock, United States

About the trial

What the trial wants to find out

Neurofibromatosis type 1 is a common genetic disease with a broad spectrum of clinical manifestations in multiple organs of the body. This project will study the (dys)function of mitochondria in patients with neurofibromatosis through multiple collections of blood samples from patients and people not afflicted by neurofibromatosis (control group). This study will evaluate how the function of mitochondria changes with time and if medications and supplements can influence the function of the mitochondria. Patients will also answer questions regarding symptoms like fatigue and pain.

The 2 groups in the trial

  • NF1 Group

    This study will look to enroll 40 to 45 adults over 18 years old diagnosed with NF1.

    Treatment: Blood draw and FACIT-F and Pain Scales

  • Control Group

    This study will look to enroll 10 to 15 adults over 18 years old without NF1.

    Treatment: Blood draw

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
8 May 2025